Anzeige
Mehr »
Sonntag, 08.06.2025 - Börsentäglich über 12.000 News
5-Dollar-Kupfer. KI-Infrastruktur. Energiewende. Vizsla Copper hat die Pfunde im Boden, die jetzt zählen.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSG0 | ISIN: SE0016013460 | Ticker-Symbol: 8N1
Frankfurt
06.06.25 | 15:29
0,052 Euro
-0,76 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOSERGEN AB Chart 1 Jahr
5-Tage-Chart
BIOSERGEN AB 5-Tage-Chart

Aktuelle News zur BIOSERGEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.05.Biosergen AB: Biosergen publishes interim report for the first quarter 202576May 21, 2025: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for first quarter 2025. The interim report is available as an attached document and on the company website...
► Artikel lesen
09.05.BIOSERGEN AB: Biosergen Nomination Committee Proposes New Board Member with an Extensive Tracking Record in the Development, Commercialization and Out-Licensing of Anti-Infectives1
09.05.Notice of annual general meeting in Biosergen AB1
09.05.BIOSERGEN AB: Biosergen takes aim at climate-driven fungal infections3
30.04.BIOSERGEN AB: Biosergen publishes 2024 annual report1
BIOSERGEN Aktie jetzt für 0€ handeln
07.03.BIOSERGEN AB: Biosergen scales up for future wins3
05.03.BIOSERGEN AB: Biosergen publishes interim report for fourth quarter 20242
07.02.BIOSERGEN AB: Biosergen's CEO: "These findings open up new possibilities"3
04.02.BIOSERGEN AB: Biosergen Successfully Completes Second Cohort of BSG005 Clinical Trial, Gaining Conclusive Proof-of-Concept Data, and Confirms 2025 Objectives1
20.12.24BIOSERGEN AB: Biosergen Agrees to Accelerated Dosing Escalation in Ongoing Second Cohort of Clinical Trial4
08.11.24Biosergen AB: Biosergen publishes interim report for third quarter 2024123Friday November 8, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the third quarter 2024. The interim report is available as an attached document and on the...
► Artikel lesen
07.10.24Biosergen AB: Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial135October 7, 2024 - Biosergen AB ("Biosergen"), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, today announced the successful enrollment of the first...
► Artikel lesen
12.06.24Karolinska Development AB (publ): Karolinska Development's portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection183STOCKHOLM, Sweden, June 12 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has received the final permission required to test its lead...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1